References

Follistim Pen™

1. Pang S, Kaplan B, Karande V, Westphal LM, Scott R, Givens C, Sacks P; Follistim Pen™ COH Study Group. Self-administration of Follistim ® AQ (in cartridge) in women undergoing controlled ovarian hyperstimulation (COH): ease of use, safety, and efficacy of the Follistim Pen™. Presented at the annual meeting of the Pacific Coast Reproductive Society, April 23–27, 2003, Rancho Mirage, California.
   
   
2. Craenmehr E, Bontje PM, Hoomans E, Voortman G, Mannaerts BMJL. Follitropin-ß administered by pen device has superior local tolerance compared with follitropin-• administered by conventional syringe. Reproductive BioMedicine Online. 2001;3:185-189. 3. Kettel LM, Scholl G, Bonaventura
   
   
3. L, Pang S, Sacks P, Chantilis S. The Follistim Pen™ OI Study Group. Evaluation of Follistim Pen™ injector for self-administration of Follistim® AQ (in cartridge) in women undergoing ovulation induction. Presented at the annual meeting of the Pacific Coast Reproductive Society, April 23–27, 2003, Rancho Mirage, California.

Infertility

1. American society for Reproductive Medicine, 1998

 Treatment options/Additional medications (Insulin sensitizing agents)

1. Nestler JE, Stovall D, Akhter N, Iuorno MJ, Jakubowicz DJ.
   Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome. Fertil Steril. 2002;77(2):209-215

Follistim AQ Cartridge/FollistimAQ vial (Recombinant DNA)

1. Coelingh Bennink HJT, Fauser BCJM, Out HJ. Recombinant follicle-stimulating hormone (FSH; Puregon) is more efficient than urinary FSH (Metrodin) in women with clomiphene citrate-resistant, normogonadotropic, chronic an ovulation: a prospective, multicenter, assessor-blind, randomized, clinical trial. European Puregon Collaborative Anovulation Study Group. Fertil Steril. 1998;69:19-25.
   
   
2. Hoomans EHM, Andersen AN, Loft A, Leerentveld RA, van Kamp AA, Zech H. A prospective, randomized clinical trial comparing 150 IU recombinant follicle stimulating hormone (Puregon®) and 225 IU highly purified urinary follicle stimulating hormone (Metrodin-HP®) in a fixed-dose regimen in women undergoing ovarian stimulation. Hum Reprod. 1999;14:2442-2447.
   
   
3. IMS America—National Audit™ Plus, Fertility products; December, 2003.
   
   
4. Out HJ, Mannaerts BMJL, Driessen SGAJ, Coelingh Bennink HJT. A prospective, randomized, assessor-blind, multicentre study comparing recombinant and urinary follicle-stimulating hormone (Puregon versus Metrodin) in in vitro fertilization. Hum Reprod. 1995;10:2534-2540.
   

Treatment options/Ovulation induction/Additional medications (Treatment of prolactin & thyroid disorders)

Do not ovulate

1. Yen SSC. Chronic anovulation caused by peripheral endocrine disorders. In: Yen SSC, Jaffe RB, eds. Reproductive Endocrinology. 3rd ed. Philadelphia, PA: W. B. Saunders Company; 1991:576-630

Bromocriptine

1. DeVane GW, Guzick DS. Bromocriptine therapy in normoprolactinemic women with unexplained infertility and galactorrhea. Fertil Steril.1986;46:1026-1031

Treatment options/Ovulation induction/Additional medications (Elevated androgens)

1. Yen SSC. Chronic anovulation caused by peripheral endocrinedisorders. In: Yen SSC, Jaffe RB, eds. Reproductive Endocrinology. 3rd ed. Philadelphia, PA: W. B. Saunders Company; 1991:576-630

Benefits

1. Fertinex™ full Prescribing Information. Randolph, Mass: Serono Laboratories, Inc; 1999.
   
   
2. Follistim® full Prescribing Information. West Orange, NJ: Organon USA Inc; 1998.
   
   
3. Out HJ, Mannaerts BMJL, Driessen SGAJ, Coelingh Bennink HJT. A prospective, randomized, assessor-blind, multicentre study comparing recombinant and urinary follicle-stimulating hormone (Puregon versus Metrodin) in in-vitro fertilization. Hum Reprod. 1995;10:2534-2540.
   
   
4. Nardi RV, Dickey RP, Thornton M, Nichols J, Fein SH, Marshall DC. A randomized, open-label, parallel group, multi-center efficacy study comparing FERRING hFSH™ SC, FERRING hFSH™ IM, and Follistim® SC in female patients undergoing in vitro fertilization [abstract]. Fertil Steril. 2001;75(suppl 1):13S. Abstract P-13.
   
   
5. Nardi RV, Feigenbaum S, Miller P, Kaufmann R, Fein SH, Marshall DC. A randomized, open-label, parallel group, multi-center efficacy study in oligoanovulatory infertile patients comparing FERRING hFSH™ SC, FERRING hFSH™ IM, and Follistim® SC for ovulation induction [abstract]. Fertil Steril. 2001;75(suppl 1): 13S. Abstract P-14.
   
   
6. Shoham Z, Insler V. Recombinant technique and gonadotropins production: new era in reproductive medicine. Fertil Steril. 1996;66:187-201.

Taking control

The information in this section was contributed by:

• Barbara Povlas Zimaras, R.N.C.
  Infertility Nurse Specialist for;
  Charles H. DeBrovner,
  M.D. Caryn E. Selick, M.D.
  
  
• Jeri L. Alper, R.N., M.S.N.
  Administrator
  Mount Sinai Division of Reproductive Endocrinology
  
  
• Terri J. Smith, L.P.N.
  The Institute for Reproductive Medicine and Science of Saint Barnabas